The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adults;Caractéristiques cholangiographiques des formes sévères de cholangiopathie associée aux anomalies du gène ABCB4/MDR3

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 6-7, 2010, Pages 380-387

  Poupon, R ^a,b,c   Arrive, L ^c   Rosmorduc, O ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B4; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BILE DUCT DILATATION; BILE DUCT DISEASE; BILE DUCT STONE; CHOLANGITIS; CHOLECYSTECTOMY; CHOLESTASIS; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; FEMALE; GALLSTONE; GENE MUTATION; HUMAN; INTRAHEPATIC BILE DUCT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PREVALENCE;

ADULT; BILE DUCTS, INTRAHEPATIC; CHOLAGOGUES AND CHOLERETICS; CHOLANGIOGRAPHY; CHOLANGITIS; CHOLELITHIASIS; DILATATION, PATHOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; P-GLYCOPROTEINS; PHENOTYPE; URSODEOXYCHOLIC ACID;

EID: 77955368965     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.04.011     Document Type: Article

References (16)

1. Nakayama F., Koga A. Hepatolithiasis: present status. World journal of surgery 1984, 8:9-14.
2. Nakayama F., Soloway R.D., Nakama T., Miyazaki K., Ichimiya H., Sheen P.C., et al. Hepatolithiasis in East Asia. Retrospective study. Digestive and liver disease 1986, 31:21-26.
3. Tazuma S. Gallstone disease: Epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intrahepatic). Best practice & research. Clinical gastroenterology 2006, 20:1075-1083.
4. Shoda J., Inada Y., Osuga T. Molecular pathogenesis of hepatolithiasis-a type of low phospholipid-associated cholelithiasis. Frontiers in bioscience 2006, 11:669-675.
5. Rosmorduc O., Hermelin B., Boelle P.Y., Parc R., Taboury J., Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003, 125:452-459.
6. Rosmorduc O., Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet journal of rare diseases 2007, 2:29.
7. Rosmorduc O., Hermelin B., Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001, 120:1459-1467.
8. Shoda J., Oda K., Suzuki H., Sugiyama Y., Ito K., Cohen D.E., et al. Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi. Hepatology 2001, 33:1194-1205.
9. Rosmorduc O., Hermelin B., Boelle P.Y., Poupon R.E., Poupon R., Chazouilleres O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 2004, 126:1220-1222. [author reply 1222-1223].
10. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Weiglein A.H., Lammert F., et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123:1238-1251.
11. Shoda J., Kano M., Asano T., Irimura T., Ueda T., Iwasaki R., et al. Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis. Hepatology 1999, 29:1026-1036.
12. Ikegami T., Matsuzaki Y., Fukushima S., Shoda J., Olivier J.L., Bouscarel B., et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005, 41:896-905.
13. Chignard N., Poupon R. Targeting farnesoid x receptor in hepatic and biliary inflammatory diseases. Gastroenterology 2009, 137:734-735. [discussion 736].
14. Kok T., Bloks V.W., Wolters H., Havinga R., Jansen P.L., Staels B., et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. The Biochemical journal 2003, 369:539-547.
15. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M., et al. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochemical and biophysical research communications 2002, 290:131-139.
16. Shoda J., Inada Y., Tsuji A., Kusama H., Ueda T., Ikegami T., et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. Journal of lipid research 2004, 45:1813-1825.